SR-B1-targeted nanodelivery of anti-cancer agents: A promising new approach to treat triplenegative breast cancer

Rebecca Johnson; Nirupama Sabnis; Xiangle Sun; Ruhani Ahluwalia; Andras G. Lacko

doi:10.2147/BCTT.S131038

SR-B1-targeted nanodelivery of anti-cancer agents: A promising new approach to treat triplenegative breast cancer

Rebecca Johnson, Nirupama Sabnis, Xiangle Sun, Ruhani Ahluwalia, Andras G. Lacko

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Patients with triple-negative breast cancer (TNBC) have a considerably less favorable prognosis than those with hormone-positive breast cancers. TNBC patients do not respond to current endocrine treatment and have a 5-year survival prognosis of <30%. The research presented here is intended to fill a void toward the much needed development of improved treatment strategies for metastatic TNBC. The overall goal of this research was to evaluate the effectiveness of reconstituted high-density lipoprotein (rHDL) nanoparticles (NPs) as delivery agents for anti-TNBC drugs. Using lapatinib and valrubicin as components of the rHDL/drug complexes resulted in a significantly better performance of the NP-transported drugs compared with their free (unencapsulated) counterparts. The enhancement of the therapeutic effect and the protection of normal cells (cardiomyocytes) achieved via the rHDL NPs were likely due to the overexpression of the high-density lipoprotein (HDL) (scavenger receptor class B type 1 [SR-B1]) receptor by the TNBC cells.

Original language	English
Pages (from-to)	383-392
Number of pages	10
Journal	Breast Cancer: Targets and Therapy
Volume	9
DOIs	https://doi.org/10.2147/BCTT.S131038
State	Published - 2 Jun 2017

Keywords

Breast cancer
Lapatinib
RHDL nanoparticles
SR-B1 receptors
TNBC
Targeted drug delivery
Valrubicin

Access to Document

10.2147/BCTT.S131038

Cite this

@article{30c50081bc3d4765badd90094f9cc650,

title = "SR-B1-targeted nanodelivery of anti-cancer agents: A promising new approach to treat triplenegative breast cancer",

abstract = "Patients with triple-negative breast cancer (TNBC) have a considerably less favorable prognosis than those with hormone-positive breast cancers. TNBC patients do not respond to current endocrine treatment and have a 5-year survival prognosis of <30%. The research presented here is intended to fill a void toward the much needed development of improved treatment strategies for metastatic TNBC. The overall goal of this research was to evaluate the effectiveness of reconstituted high-density lipoprotein (rHDL) nanoparticles (NPs) as delivery agents for anti-TNBC drugs. Using lapatinib and valrubicin as components of the rHDL/drug complexes resulted in a significantly better performance of the NP-transported drugs compared with their free (unencapsulated) counterparts. The enhancement of the therapeutic effect and the protection of normal cells (cardiomyocytes) achieved via the rHDL NPs were likely due to the overexpression of the high-density lipoprotein (HDL) (scavenger receptor class B type 1 [SR-B1]) receptor by the TNBC cells.",

keywords = "Breast cancer, Lapatinib, RHDL nanoparticles, SR-B1 receptors, TNBC, Targeted drug delivery, Valrubicin",

author = "Rebecca Johnson and Nirupama Sabnis and Xiangle Sun and Ruhani Ahluwalia and Lacko, {Andras G.}",

note = "Funding Information: This research was supported by the Cancer Prevention and Research Institute of Texas (DP150091); Wheels for Wellness, Fort Worth, TX, USA; and the Rutledge Foundation. Publisher Copyright: {\textcopyright} 2017 Johnson et al.",

year = "2017",

month = jun,

day = "2",

doi = "10.2147/BCTT.S131038",

language = "English",

volume = "9",

pages = "383--392",

journal = "Breast Cancer: Targets and Therapy",

issn = "1179-1314",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - SR-B1-targeted nanodelivery of anti-cancer agents

T2 - A promising new approach to treat triplenegative breast cancer

AU - Johnson, Rebecca

AU - Sabnis, Nirupama

AU - Sun, Xiangle

AU - Ahluwalia, Ruhani

AU - Lacko, Andras G.

N1 - Funding Information: This research was supported by the Cancer Prevention and Research Institute of Texas (DP150091); Wheels for Wellness, Fort Worth, TX, USA; and the Rutledge Foundation. Publisher Copyright: © 2017 Johnson et al.

PY - 2017/6/2

Y1 - 2017/6/2

N2 - Patients with triple-negative breast cancer (TNBC) have a considerably less favorable prognosis than those with hormone-positive breast cancers. TNBC patients do not respond to current endocrine treatment and have a 5-year survival prognosis of <30%. The research presented here is intended to fill a void toward the much needed development of improved treatment strategies for metastatic TNBC. The overall goal of this research was to evaluate the effectiveness of reconstituted high-density lipoprotein (rHDL) nanoparticles (NPs) as delivery agents for anti-TNBC drugs. Using lapatinib and valrubicin as components of the rHDL/drug complexes resulted in a significantly better performance of the NP-transported drugs compared with their free (unencapsulated) counterparts. The enhancement of the therapeutic effect and the protection of normal cells (cardiomyocytes) achieved via the rHDL NPs were likely due to the overexpression of the high-density lipoprotein (HDL) (scavenger receptor class B type 1 [SR-B1]) receptor by the TNBC cells.

AB - Patients with triple-negative breast cancer (TNBC) have a considerably less favorable prognosis than those with hormone-positive breast cancers. TNBC patients do not respond to current endocrine treatment and have a 5-year survival prognosis of <30%. The research presented here is intended to fill a void toward the much needed development of improved treatment strategies for metastatic TNBC. The overall goal of this research was to evaluate the effectiveness of reconstituted high-density lipoprotein (rHDL) nanoparticles (NPs) as delivery agents for anti-TNBC drugs. Using lapatinib and valrubicin as components of the rHDL/drug complexes resulted in a significantly better performance of the NP-transported drugs compared with their free (unencapsulated) counterparts. The enhancement of the therapeutic effect and the protection of normal cells (cardiomyocytes) achieved via the rHDL NPs were likely due to the overexpression of the high-density lipoprotein (HDL) (scavenger receptor class B type 1 [SR-B1]) receptor by the TNBC cells.

KW - Breast cancer

KW - Lapatinib

KW - RHDL nanoparticles

KW - SR-B1 receptors

KW - TNBC

KW - Targeted drug delivery

KW - Valrubicin

UR - http://www.scopus.com/inward/record.url?scp=85020450180&partnerID=8YFLogxK

U2 - 10.2147/BCTT.S131038

DO - 10.2147/BCTT.S131038

M3 - Article

AN - SCOPUS:85020450180

SN - 1179-1314

VL - 9

SP - 383

EP - 392

JO - Breast Cancer: Targets and Therapy

JF - Breast Cancer: Targets and Therapy

ER -

SR-B1-targeted nanodelivery of anti-cancer agents: A promising new approach to treat triplenegative breast cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this